专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20100183615A1 CROSS-SPECIES-SPECIFIC BISPECIFIC BINDERS 审中-公开
标题翻译：跨物种特异性双重绑定
公开(公告)号：US20100183615A1
公开(公告)日：2010-07-22
申请号：US12594729
申请日：2008-04-03
申请人： Peter Kufer , Tobias Raum , Roman Kischel , Ralf Lutterbuese , Patrick Hoffmann , Matthias Klinger , Doris Rau , Susanne Mangold
发明人： Peter Kufer , Tobias Raum , Roman Kischel , Ralf Lutterbuese , Patrick Hoffmann , Matthias Klinger , Doris Rau , Susanne Mangold
IPC分类号： A61K39/395 , C07K16/00 , C07H21/04 , A61P35/00 , A61P37/00 , C12N15/74 , C12N5/10
CPC分类号： C07K16/2809 , C07K16/2863 , C07K16/30 , C07K16/3053 , C07K16/32 , C07K16/40 , C07K16/4291 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/565 , C07K2317/622 , C07K2317/626 , C07K2317/73 , C07K2317/90 , C07K2317/92 , C07K2319/32 , C07K2319/43
摘要： The present invention relates to a polypeptide comprising a first human binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 (epsilon) chain and a second binding domain capable of binding to EGFR, Her2/neu or IgE of a human and/or a non-chimpanzee primate as well as to a process for the production of the mentioned polypeptide. The invention further relates to nucleic acids encoding for the polypeptide, to vectors comprising the same and to host cells comprising the vector. In another aspect, the invention provides for a pharmaceutical composition comprising the mentioned polypeptide and medical uses of the polypeptide.
摘要翻译：本发明涉及包含能够结合人和非黑猩猩灵长类CD3（ε）链的表位的第一人结合结构域和能够结合人的EGFR，Her2 / neu或IgE的第二结合结构域的多肽和/或非黑猩猩灵长类动物以及生产所述多肽的方法。本发明还涉及编码多肽的核酸，包含其的载体和包含载体的宿主细胞。另一方面，本发明提供包含所述多肽的药物组合物和多肽的医学用途。

2. 发明授权

US08901278B2 Pharmaceutical antibody compositions with resistance to soluble CEA 有权
标题翻译：具有抗CEA抗性的药物抗体组合物
公开(公告)号：US08901278B2
公开(公告)日：2014-12-02
申请号：US13324823
申请日：2011-12-13
申请人： Doris Rau , Susanne Mangold , Peter Kufer , Tobias Raum
发明人： Doris Rau , Susanne Mangold , Peter Kufer , Tobias Raum
IPC分类号： C07K16/30 , A61K39/00
CPC分类号： C07K16/3007 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/732
摘要： The present invention relates to pharmaceutical compositions for the treatment of an epithelial tumor in a human, said pharmaceutical composition comprising an IgG1 antibody specifically binding to human CEA, wherein the variable region of said IgG1 antibody comprises at least (i) a CDR-H1 having the amino acid sequence “SYWMH” (SEQ ID NO: 29) and a CDR-H2 having the amino acid sequence “FIRNKANGGTTEYAASVKG” (SEQ ID NO: 28) and a CDR-H3 having the amino acid sequence “DRGLRFYFDY” (SEQ ID NO: 27) or (ii) a CDR-H1 having the amino acid sequence “TYAMH” (SEQ ID NO: 31) and a CDR-H2 having the amino acid sequence “LISNDGSNKYYADSVKG” (SEQ ID NO: 30) and a CDR-H3 having the amino acid sequence “DRGLRFYFDY” (SEQ ID NO: 27). Furthermore, processes for the production of said pharmaceutical compositions as well as medical/pharmaceutical uses for the IgG1 antibody molecules bearing specificities for the human CEA antigen are disclosed.
摘要翻译：本发明涉及用于治疗人类上皮肿瘤的药物组合物，所述药物组合物包含与人CEA特异性结合的IgG1抗体，其中所述IgG1抗体的可变区至少包含（i）具有氨基酸序列“SYWMH”（SEQ ID NO：29）和具有氨基酸序列“FIRNKANGGTTEYAASVKG”（SEQ ID NO：28）的CDR-H2和具有氨基酸序列“DRGLRFYFDY”（SEQ ID NO：（SEQ ID NO：31）的CDR-H1和具有氨基酸序列“LISNDGSNKYYADSVKG”（SEQ ID NO：30）的CDR-H2和CDR -H3，具有氨基酸序列“DRGLRFYFDY”（SEQ ID NO：27）。此外，公开了用于生产所述药物组合物的方法以及具有人CEA抗原特异性的IgG1抗体分子的医疗/药物用途。

3. 发明授权

US10981998B2 Cross-species-specific single domain bispecific single chain antibody 有权
公开(公告)号：US10981998B2
公开(公告)日：2021-04-20
申请号：US13122280
申请日：2009-10-01
申请人： Peter Kufer , Tobias Raum , Roman Kischel , Ralf Lutterbüse , Patrick Hoffman , Matthias Klinger , Doris Rau , Susanne Mangold
发明人： Peter Kufer , Tobias Raum , Roman Kischel , Ralf Lutterbüse , Patrick Hoffman , Matthias Klinger , Doris Rau , Susanne Mangold
IPC分类号： C07K16/28
摘要： The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain consisting of one antibody variable domain capable of binding to an epitope of the human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain capable of binding to an epitope of a human and a non-chimpanzee primate tumor target antigen. The invention further relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3ϵ (epsilon) chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain consisting of one antibody variable domain capable of binding to an epitope of a human and a non-chimpanzee primate tumor target antigen. The invention also provides nucleic acids encoding said bispecific single chain antibody molecule as well as vectors and host cells and a process for its production. The invention further relates to pharmaceutical compositions comprising said bispecific single chain antibody molecule and medical uses of said bispecific single chain antibody molecule.

4. 发明授权

US09587036B2 Cross-species-specific PSMAxCD3 bispecific single chain antibody 有权
标题翻译：跨物种特异性PSMAxCD3双特异性单链抗体
公开(公告)号：US09587036B2
公开(公告)日：2017-03-07
申请号：US13638223
申请日：2011-04-01
申请人： Peter Kufer , Ralf Lutterbuese , Matthias Klinger , Petra Fluhr , Doris Rau , Susanne Hausmann , Carola Steiger , Tobias Raum , Patrick Hoffmann , Roman Kischel , Evelyne Schaller , Susanne Mangold
发明人： Peter Kufer , Ralf Lutterbuese , Matthias Klinger , Petra Fluhr , Doris Rau , Susanne Hausmann , Carola Steiger , Tobias Raum , Patrick Hoffmann , Roman Kischel , Evelyne Schaller , Susanne Mangold
IPC分类号： C07K16/46 , A61K39/395 , C07K16/28 , C07K16/30
CPC分类号： C07K16/468 , C07K16/2809 , C07K16/30 , C07K16/3069 , C07K2317/31 , C07K2317/33 , C07K2317/622
摘要： The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain capable of binding to prostate-specific membrane antigen (PSMA). The invention also provides nucleic acids encoding said bispecific single chain antibody molecule as well as vectors and host cells and a process for its production. The invention further relates to pharmaceutical compositions comprising said bispecific single chain antibody molecule and medical uses of said bispecific single chain antibody molecule.
摘要翻译：本发明涉及双特异性单链抗体分子，其包含能够结合人和非黑猩猩灵长类CD3ε链的表位的第一结合结构域，其中所述表位是包含在SEQ ID NO：1中的氨基酸序列的一部分身份证号 2,4,6和8以及能够结合前列腺特异性膜抗原（PSMA）的第二结合结构域。本发明还提供了编码所述双特异性单链抗体分子以及载体和宿主细胞的核酸及其生产方法。本发明还涉及包含所述双特异性单链抗体分子的药物组合物和所述双特异性单链抗体分子的医学应用。

5. 发明申请

US20120121600A1 PHARMACEUTICAL ANTIBODY COMPOSITIONS WITH RESISTANCE TO SOLUBLE CEA 有权
标题翻译：具有抗溶性CEA的药物抗体组合物
公开(公告)号：US20120121600A1
公开(公告)日：2012-05-17
申请号：US13324823
申请日：2011-12-13
申请人： Doris RAU , Susanne Mangold , Peter Kufer , Tobias Raum
发明人： Doris RAU , Susanne Mangold , Peter Kufer , Tobias Raum
IPC分类号： A61K39/395 , A61P35/00 , C07K16/32
CPC分类号： C07K16/3007 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/732
摘要： The present invention relates to pharmaceutical compositions for the treatment of an epithelial tumor in a human, said pharmaceutical composition comprising an IgG1 antibody specifically binding to human CEA, wherein the variable region of said IgG1 antibody comprises at least (i) a CDR-H1 having the amino acid sequence “SYWMH” and a CDR-H2 having the amino acid sequence “FIRNKANGGTTEYAASVKG” and a CDR-H3 having the amino acid sequence “DRGLRFYFDY” or (ii) a CDR-H1 having the amino acid sequence “TYAMH” and a CDR-H2 having the amino acid sequence “LISNDGSNKYYADSVKG” and a CDR-H3 having the amino acid sequence “DRGLRFYFDY”. Furthermore, processes for the production of said pharmaceutical compositions as well as medical/pharmaceutical uses for the IgG1 antibody molecules bearing specificities for the human CEA antigen are disclosed.
摘要翻译：本发明涉及用于治疗人类上皮肿瘤的药物组合物，所述药物组合物包含与人CEA特异性结合的IgG1抗体，其中所述IgG1抗体的可变区至少包含（i）具有氨基酸序列“SYWMH”和具有氨基酸序列“FIRNKANGGTTEYAASVKG”的CDR-H2和具有氨基酸序列“DRGLRFYFDY”的CDR-H3或（ii）具有氨基酸序列“TYAMH”的CDR-H1和具有氨基酸序列“LISNDGSNKYYADSVKG”的CDR-H2和具有氨基酸序列“DRGLRFYFDY”的CDR-H3。此外，公开了用于生产所述药物组合物的方法以及具有人CEA抗原特异性的IgG1抗体分子的医疗/药物用途。

6. 发明申请

US20090226444A1 PHARMACEUTICAL ANTIBODY COMPOSITIONS WITH RESISTANCE TO SOLUBLE CEA 审中-公开
标题翻译：具有抗溶性CEA的药物抗体组合物
公开(公告)号：US20090226444A1
公开(公告)日：2009-09-10
申请号：US12095952
申请日：2006-12-21
申请人： Doris Rau , Susanne Mangold , Peter Kufer , Tobias Raum
发明人： Doris Rau , Susanne Mangold , Peter Kufer , Tobias Raum
IPC分类号： C07K16/30 , C12P21/08 , C12N15/85 , A61K39/395 , A61K48/00 , A61K31/7088 , A61P35/04
CPC分类号： C07K16/3007 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/732
摘要： The present invention relates to pharmaceutical compositions for the treatment of an epithelial tumor in a human, said pharmaceutical composition comprising an IgG1 antibody specifically binding to human CEA, wherein the variable region of said IgG1 antibody comprises at least (i) a CDR-H1 having the amino acid sequence “SYWMH” (SEQ ID NO: 29) and a CDR-H2 having the amino acid sequence “FIRNKANGGTTEYAASVKG” (SEQ ID NO: 28) and a CDR-H3 having the amino acid sequence “DRGLRFYFDY” (SEQ ID NO: 27) or (ii) a CDR-H1 having the amino acid sequence “TYAMH” (SEQ ID NO: 31) and a CDR-H2 having the amino acid sequence “LISNDGSNKYYADSVKG” (SEQ ID NO: 30) and a CDR-H3 having the amino acid sequence “DRGLRFYFDY” (SEQ ID NO: 27). Furthermore, processes for the production of said pharmaceutical compositions as well as medical/pharmaceutical uses for the IgG1 antibody molecules bearing specificities for the human CEA antigen are disclosed.
摘要翻译：本发明涉及用于治疗人类上皮肿瘤的药物组合物，所述药物组合物包含与人CEA特异性结合的IgG1抗体，其中所述IgG1抗体的可变区至少包含（i）具有氨基酸序列“SYWMH”（SEQ ID NO：29）和具有氨基酸序列“FIRNKANGGTTEYAASVKG”（SEQ ID NO：28）的CDR-H2和具有氨基酸序列“DRGLRFYFDY”（SEQ ID NO：（SEQ ID NO：31）的CDR-H1和具有氨基酸序列“LISNDGSNKYYADSVKG”（SEQ ID NO：30）的CDR-H2和CDR -H3，具有氨基酸序列“DRGLRFYFDY”（SEQ ID NO：27）。此外，公开了用于生产所述药物组合物的方法以及具有人CEA抗原特异性的IgG1抗体分子的医疗/药物用途。

7. 发明申请

US20090226432A1 PHARMACEUTICAL COMPOSITIONS WITH RESISTANCE TO SOLUBLE CEA 有权
标题翻译：具有抗溶剂性能的药物组合物
公开(公告)号：US20090226432A1
公开(公告)日：2009-09-10
申请号：US12158611
申请日：2006-12-21
申请人： Ralf Lutterbüse , Petra Mayer , Evelyne Schaller , Doris Rau , Susanne Mangold , Peter Kufer , Alexander Murr , Tobias Raum , Monika Wissinger
发明人： Ralf Lutterbüse , Petra Mayer , Evelyne Schaller , Doris Rau , Susanne Mangold , Peter Kufer , Alexander Murr , Tobias Raum , Monika Wissinger
IPC分类号： A61K39/395 , A61K31/7088 , C12P21/04
CPC分类号： C07K16/468 , A61K39/39558 , A61K45/06 , C07K16/2809 , C07K16/3007 , C07K16/46 , C07K2317/21 , C07K2317/31 , C07K2317/565 , C07K2319/00
摘要： The present invention relates to pharmaceutical compositions for the treatment of an epithelial tumor in a human, said pharmaceutical composition comprising a bispecific single chain antibody which has a first binding domain specifically binding to human CD3, and a second binding domain specifically binding to human CEA, wherein said second binding domain comprises at least a part of the CDR-H3 or the complete CDR-H3 of murine monoclonal antibody A5B7. Furthermore, processes for the production of said pharmaceutical compositions as well as medical/pharmaceutical uses for the specific bispecific single chain antibody molecules bearing specificities for the human CD3 antigen and the human CEA antigen are disclosed.
摘要翻译：本发明涉及用于治疗人类上皮肿瘤的药物组合物，所述药物组合物包含具有特异性结合人CD3的第一结合结构域的双特异性单链抗体和特异性结合人CEA的第二结合结构域，其中所述第二结合结构域包含鼠单克隆抗体A5B7的CDR-H3或完整CDR-H3的至少一部分。此外，公开了用于生产所述药物组合物的方法以及对于人CD3抗原和人CEA抗原具有特异性的特异性双特异性单链抗体分子的医学/药物用途。

8. 发明申请

US20130129730A1 CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY 有权
标题翻译：交叉特异性PSMAxCD3双相单链抗体
公开(公告)号：US20130129730A1
公开(公告)日：2013-05-23
申请号：US13638223
申请日：2011-04-01
申请人： Peter Kufer , Ralf Lutterbuese , Matthias Klinger , Petra Fluhr , Doris Rau , Susanne Hausmann , Carole Steiger , Tobias Raum , Patrick Hoffmann , Roman Kischel , Evelyne Schaller , Susanne Mangold
发明人： Peter Kufer , Ralf Lutterbuese , Matthias Klinger , Petra Fluhr , Doris Rau , Susanne Hausmann , Carole Steiger , Tobias Raum , Patrick Hoffmann , Roman Kischel , Evelyne Schaller , Susanne Mangold
IPC分类号： C07K16/46
CPC分类号： C07K16/468 , C07K16/2809 , C07K16/30 , C07K16/3069 , C07K2317/31 , C07K2317/33 , C07K2317/622
摘要： The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain capable of binding to prostate-specific membrane antigen (PSMA). The invention also provides nucleic acids encoding said bispecific single chain antibody molecule as well as vectors and host cells and a process for its production. The invention further relates to pharmaceutical compositions comprising said bispecific single chain antibody molecule and medical uses of said bispecific single chain antibody molecule.
摘要翻译：本发明涉及双特异性单链抗体分子，其包含能够结合人和非黑猩猩灵长类CD3ε链的表位的第一结合结构域，其中所述表位是包含在SEQ ID NO：1中的氨基酸序列的一部分身份证号 2,4,6和8以及能够结合前列腺特异性膜抗原（PSMA）的第二结合结构域。本发明还提供了编码所述双特异性单链抗体分子以及载体和宿主细胞的核酸及其生产方法。本发明还涉及包含所述双特异性单链抗体分子的药物组合物和所述双特异性单链抗体分子的医学应用。

9. 发明授权

US08394926B2 Pharmaceutical compositions with resistance to soluble CEA 有权
标题翻译：具有抗CEA抗性的药物组合物
公开(公告)号：US08394926B2
公开(公告)日：2013-03-12
申请号：US12158611
申请日：2006-12-21
申请人： Ralf Lutterbüse , Petra Mayer , Evelyne Schaller , Doris Rau , Susanne Mangold , Peter Kufer , Alexander Murr , Tobias Raum , Monika Wissinger
发明人： Ralf Lutterbüse , Petra Mayer , Evelyne Schaller , Doris Rau , Susanne Mangold , Peter Kufer , Alexander Murr , Tobias Raum , Monika Wissinger
IPC分类号： C12P21/08
CPC分类号： C07K16/468 , A61K39/39558 , A61K45/06 , C07K16/2809 , C07K16/3007 , C07K16/46 , C07K2317/21 , C07K2317/31 , C07K2317/565 , C07K2319/00
摘要： The present disclosure relates to a bispecific single chain antibody which has a first binding domain specifically binding to human CD3, and a second binding domain specifically binding to human CEA, where the second binding domain comprises at least a part of the CDR-H3 or the complete CDR-H3 of murine monoclonal antibody A5B7, a pharmaceutical composition comprising the bispecific single chain antibody, and methods for the treatment of an epithelial tumor in a human with the pharmaceutical compositions containing the bispecific single chain antibody. Furthermore, processes for the production of the pharmaceutical compositions as well as medical/pharmaceutical uses for the specific bispecific single chain antibody molecules bearing specificities for the human CD3 antigen and the human CEA antigen are disclosed.
摘要翻译：本公开内容涉及具有特异性结合人CD3的第一结合结构域和特异性结合人CEA的第二结合结构域的双特异性单链抗体，其中第二结合结构域包含至少一部分CDR-H3或含有双特异性单链抗体的单克隆抗体A5B7的完整CDR-H3，包含双特异性单链抗体的药物组合物，以及用含有双特异性单链抗体的药物组合物治疗人的上皮肿瘤的方法。此外，公开了用于生产药物组合物的方法以及具有对人CD3抗原和人CEA抗原具有特异性的特异性双特异性单链抗体分子的医学/药物用途。

10. 发明申请

US20120034228A1 CROSS-SPECIES-SPECIFIC PSCAxCD3, CD19xCD3, C-METxCD3, ENDOSIALINxCD3, EPCAMxCD3, IGF-1RxCD3 OR FAPALPHAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY 审中-公开
标题翻译：交叉特异性PSCAxCD3，CD19xCD3，C-METxCD3，ENDOSIALINXCD3，EPCAMxCD3，IGF-1RxCD3或FAPALPHAxCD3双链单链抗体
公开(公告)号：US20120034228A1
公开(公告)日：2012-02-09
申请号：US13122242
申请日：2009-10-01
申请人： Peter Kufer , Tobias Raum , Roman Kischel , Ralf Lutterbüse , Patrick Hoffmann , Doris Rau , Matthias Klinger , Susanne Mangold , Claudia Blümel
发明人： Peter Kufer , Tobias Raum , Roman Kischel , Ralf Lutterbüse , Patrick Hoffmann , Doris Rau , Matthias Klinger , Susanne Mangold , Claudia Blümel
IPC分类号： A61K39/395 , C12N15/62 , C12N15/63 , C12P21/02 , A61P35/02 , C12N1/19 , C12N5/10 , C12N1/15 , A61P35/00 , C07K16/46 , C12N1/21
CPC分类号： C07K16/2809 , A61K2039/505 , C07K16/22 , C07K16/2803 , C07K16/2851 , C07K16/2863 , C07K16/30 , C07K16/3069 , C07K16/40 , C07K2317/31 , C07K2317/34
摘要： The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain capable of binding to an antigen selected from the group consisting of Prostate Stem Cell Antigen (PSCA), B-Lymphocyte antigen CD19 (CD19), hepatocyte growth factor receptor (C-MET), Endosialin, the EGF-like domain 1 of EpCAM, encoded by exon 2, Fibroblast activation protein alpha (FAP alpha) and Insulin-like growth factor I receptor (IGF-IR or IGF-1R). The invention also provides nucleic acids encoding said bispecific single chain antibody molecule as well as vectors and host cells and a process for its production. The invention further relates to pharmaceutical compositions comprising said bispecific single chain antibody molecule and medical uses of said bispecific single chain antibody molecule.
摘要翻译：本发明涉及双特异性单链抗体分子，其包含能够结合人和非黑猩猩灵长类CD3ε链的表位的第一结合结构域，其中所述表位是包含在SEQ ID NO：1中的氨基酸序列的一部分身份证号 2,4,6和8以及能够结合选自前列腺干细胞抗原（PSCA），B-淋巴细胞抗原CD19（CD19），肝细胞生长因子受体（C- MET），内皮唾液酸蛋白，由外显子2编码的EpCAM的EGF样结构域1，成纤维细胞激活蛋白α（FAPα）和胰岛素样生长因子I受体（IGF-1R或IGF-1R）。本发明还提供了编码所述双特异性单链抗体分子以及载体和宿主细胞的核酸及其生产方法。本发明还涉及包含所述双特异性单链抗体分子的药物组合物和所述双特异性单链抗体分子的医学应用。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式